Molecular Center of Health and Disease

健康与疾病分子中心

基本信息

  • 批准号:
    10553864
  • 负责人:
  • 金额:
    $ 228.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-03-06 至 2028-02-29
  • 项目状态:
    未结题

项目摘要

Overall-Abstract Chronic diseases, such as heart disease, diabetes, and cancer are among the most prevalent health conditions in the United States, responsible for 7 out of every 10 deaths. Mississippi ranks first or second in 8 of 10 leading causes of death, with 90% of the population having 1-2 chronic diseases. While chronic diseases can be treated through early intervention, targeted medical therapies, and improved diet and exercise, an understanding of genetic susceptibility and molecular mechanisms involved in disease onset has the potential to halt progression and return an individual to a healthier state. Advances in technology now allow for unprecedented insight into genome complexity and its interaction with the environment using genomic, transcriptomic, proteomic, and metabolomic datasets. The integration of these datasets with physiological information using computational approaches can provide systematic insight into the molecular, cellular, and overall physiology associated with the health-disease continuum. We propose to establish a new Phase I COBRE, the Molecular Center of Health and Disease (MCHD) to facilitate research under a central theme of molecular physiology to enhance the depth of education, mentorship, and training of researchers to generate unique opportunities in the application of omics technology and computational biology. The MCHD will be comprised of multiple components including an administrative unit, education and mentoring programs, a pilot project program, two research cores, and three major project investigators. The overall objectives of the MCHD are: (1) to develop infrastructure and state-of- the-art research core facilities essential for cutting edge basic, clinical, and translational approaches to study the health and disease continuum. The MCHD, through Core B will enhance existing -omics technology (e.g., single cell RNAseq and spatial transcriptomics), proteomic capabilities, and establish a new innovative core, involving CRISPR/Cas9 gene-editing technology to interrogate gene function and biological pathways; and Core C will establish critical computing infrastructure and computational biology analysis not currently available at the University; (2) to establish meaningful education, mentoring programs, and research support for promising new investigators to nurture them into productive, independently funded investigators, who will be effective collaborators on multidisciplinary research teams. This will be accomplished through offering a “Genetic and - Omics Academy” (didactic instruction and observership) to strengthen researcher understanding of molecular and computational approaches, a robust mentoring program involving one-on-one and team mentoring, career development opportunities, and providing a high level of research support through each core; and (3) to enhance collaborations and interactions among investigators across multiple disciplines at UMMC, promote cooperation between other IDeA supported programs, including existing COBRE, IDeA-CTR, and external partnership with the Mississippi-INBRE.
总体-摘要 慢性病,如心脏病,糖尿病和癌症是最普遍的健康状况之一 在美国,每10例死亡中就有7例是由它造成的。密西西比排名第一或第二的10个领先的8个 死亡原因,90%的人口患有1-2种慢性病。虽然慢性病可以治疗, 通过早期干预,有针对性的药物治疗,以及改善饮食和锻炼, 与疾病发病有关的遗传易感性和分子机制有可能阻止疾病进展 并使个体恢复到更健康的状态。技术的进步现在允许前所未有的洞察力, 基因组复杂性及其与环境的相互作用,使用基因组学,转录组学,蛋白质组学, 代谢组学数据集这些数据集与生理信息的整合使用计算 方法可以提供系统的深入了解分子,细胞和整体生理学相关的 健康-疾病的连续体我们建议建立一个新的第一阶段COBRE,分子健康中心 和疾病(MCHD),以促进分子生理学的中心主题下的研究,以提高深度 教育,指导和培训研究人员,以创造独特的机会,在应用组学 技术和计算生物学。MCHD将由多个组件组成,包括 行政单位,教育和指导计划,试点项目计划,两个研究核心,和三个 主要项目调查员。MCHD的总体目标是:(1)发展基础设施和国家, 最先进的研究核心设施,对前沿的基础、临床和转化方法至关重要, 健康和疾病连续体。MCHD通过核心B将增强现有的组学技术(例如,单个 细胞RNAseq和空间转录组学),蛋白质组学能力,并建立一个新的创新核心, CRISPR/Cas9基因编辑技术,用于询问基因功能和生物学途径;核心C将 建立关键的计算基础设施和计算生物学分析, 大学;(2)建立有意义的教育,指导计划,并为有前途的新研究提供研究支持 调查员,培养他们成为生产力,独立资助的调查员,谁将是有效的 多学科研究团队的合作者。这将通过提供“基因和- 组学学院”(教学指导和奖学金),以加强研究人员对分子 和计算方法,一个强大的指导计划,包括一对一和团队指导,职业生涯 发展机会,并通过每个核心提供高水平的研究支持;以及(3)加强 UMMC多学科研究人员之间的合作和互动,促进合作 在其他由IDEA支持的计划之间,包括现有的COBRE、IDEA-CTR以及与 密西西比河-INBRE。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL R GARRETT其他文献

MICHAEL R GARRETT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL R GARRETT', 18)}}的其他基金

Omics, Bioinformatics and Flow Cytometry Core
组学、生物信息学和流式细胞术核心
  • 批准号:
    10630580
  • 财政年份:
    2023
  • 资助金额:
    $ 228.38万
  • 项目类别:
Project 1 - TBD
项目 1 - 待定
  • 批准号:
    10553868
  • 财政年份:
    2023
  • 资助金额:
    $ 228.38万
  • 项目类别:
Core B-Omics and Gene-Editing
核心 B 组学和基因编辑
  • 批准号:
    10553866
  • 财政年份:
    2023
  • 资助金额:
    $ 228.38万
  • 项目类别:
Core A- Administration, Education, and Mentoring
核心 A- 管理、教育和指导
  • 批准号:
    10553865
  • 财政年份:
    2023
  • 资助金额:
    $ 228.38万
  • 项目类别:
Genetic Targets of Hypertension End Organ Damage
高血压终末器官损伤的遗传靶标
  • 批准号:
    10198017
  • 财政年份:
    2018
  • 资助金额:
    $ 228.38万
  • 项目类别:
Genetic Targets of Hypertension End Organ Damage
高血压终末器官损伤的遗传靶标
  • 批准号:
    9920359
  • 财政年份:
    2018
  • 资助金额:
    $ 228.38万
  • 项目类别:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
核心 C - 基因组学、动物模型和高级表型分析核心
  • 批准号:
    10403631
  • 财政年份:
    2013
  • 资助金额:
    $ 228.38万
  • 项目类别:
Core C - Genomics, Animal Models and Advanced Phenotyping Core
核心 C - 基因组学、动物模型和高级表型分析核心
  • 批准号:
    10159921
  • 财政年份:
    2013
  • 资助金额:
    $ 228.38万
  • 项目类别:
Genetics of Renal End Organ Damage in Hypertension
高血压肾终末器官损伤的遗传学
  • 批准号:
    8477235
  • 财政年份:
    2009
  • 资助金额:
    $ 228.38万
  • 项目类别:
Genetics of Renal End Organ Damage in Hypertension
高血压肾终末器官损伤的遗传学
  • 批准号:
    8289584
  • 财政年份:
    2009
  • 资助金额:
    $ 228.38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 228.38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了